Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 175

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 175
---
examination, post grant review, interference proceedings or other patent office proceedings, inter partes
review or litigation, in the United States or elsewhere, challenging our patent rights. An adverse determination in any such submission,
proceeding or litigation could reduce the scope of, or invalidate, our patent rights, and allow third parties to commercialize our technology
or products and compete directly with us, without payment to us. In addition, if the breadth or strength of protection provided by our
patents and patent applications is threatened, it could dissuade companies from collaborating with us to exploit our intellectual property
or develop and commercialize drug candidates.

70

The issuance of a patent is not conclusive as to
the inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States,
the European Union, Australia and elsewhere. Such challenges may result in loss of ownership or in patent claims being narrowed, invalidated
or held unenforceable, in whole or in part, which could limit the duration of the patent protection of our technology and products. As
a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical
to ours.

In addition, other companies may attempt to circumvent
any regulatory data protection or market exclusivity that we obtain under applicable legislation, which may require us to allocate significant
resources to prevent such circumvention. Such developments could enable other companies to circumvent our intellectual property rights
and use our clinical trial data to obtain marketing authorizations in the European Union, Australia and in other jurisdictions. Such developments
may also require us to allocate significant resources to prevent other companies from circumventing or violating our intellectual property
rights because the legal systems of some countries do not favor the enforcement of patents, trade secrets and other intellectual property
protection, particularly those relating to healthcare, medicine, or biotechnology products, which could make it difficult for us to stop
the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce
our patent rights in international jurisdictions, whether or not successful, could result in substantial costs and divert our resources,
efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and
our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate, and the damages or other remedies awarded, if